Success Metrics

Clinical Success Rate
81.3%

Based on 13 completed trials

Completion Rate
81%(13/16)
Active Trials
0(0%)
Results Posted
31%(4 trials)
Terminated
3(18%)

Phase Distribution

Ph phase_4
4
24%
Ph phase_2
7
41%
Ph not_applicable
2
12%
Ph phase_1
2
12%

Phase Distribution

2

Early Stage

7

Mid Stage

4

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
2(13.3%)
Phase 2Efficacy & side effects
7(46.7%)
Phase 4Post-market surveillance
4(26.7%)
N/ANon-phased studies
2(13.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

76.5%

13 of 17 finished

Non-Completion Rate

23.5%

4 ended early

Currently Active

0

trials recruiting

Total Trials

17

all time

Status Distribution
Completed(13)
Terminated(4)

Detailed Status

Completed13
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
17
Active
0
Success Rate
81.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (13.3%)
Phase 27 (46.7%)
Phase 44 (26.7%)
N/A2 (13.3%)

Trials by Status

completed1376%
terminated318%
withdrawn16%

Recent Activity

0 active trials
Showing 5 of 17
completed

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

NCT04132557
completedphase_2

Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.

NCT02634684
withdrawn

Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia

NCT03999190
completedphase_1

Decision Making Study in Young and Middle-Aged Adults: Part II

NCT03512171
completedphase_4

Apathy Associated With Alzheimer's Disease

NCT00254033
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT04132557

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Completed
NCT02634684Phase 2

Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.

Completed
NCT03999190

Imaging Dopamine D2 Agonist Binding Sites in Schizophrenia

Withdrawn
NCT03512171Phase 1

Decision Making Study in Young and Middle-Aged Adults: Part II

Completed
NCT00254033Phase 4

Apathy Associated With Alzheimer's Disease

Completed
NCT01577706Not Applicable

Spectroscopic Imaging at 4T: A Drug Challenge Study

Terminated
NCT00363298Not Applicable

Dextro-Amphetamine Versus Caffeine in Treatment-resistant OCD

Completed
NCT00000304Phase 2

Dextroamphetamine as an Adjunct in Cocaine Treatment - 1

Completed
NCT00000306Phase 2

Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3

Completed
NCT00000308Phase 2

Dextroamphetamine-Cocaine Behavioral Intervention - 5

Completed
NCT01215929Phase 2

Studying Amphetamine Withdrawal in Humans

Completed
NCT00228046Phase 4

Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder

Completed
NCT01905371Phase 2

Amphetamine-Enhanced Stroke Recovery

Completed
NCT00630682Phase 2

A Pilot Trial of Dextroamphetamine for Methamphetamine Dependence

Completed
NCT00000305Phase 1

Amphetamine Cocaine Interaction Study - 2

Terminated
NCT00296686Phase 4

Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression

Terminated
NCT01220440Phase 4

Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17